Many have probably heard of uncomplicated urinary tract infections (UTIs). They're common. In fact, they are one of the most common diagnoses worldwide at ~400 million, affecting about 1 in 2 women.
Maybe you've had one yourself, or you know someone who has. It's a painful nuisance, usually treated with a short course of antibiotics, and life returns to normal within a few days. But a catheter-associated UTI (CAUTI) is a different beast entirely. It's not just a "bad UTI." It's a complex, dangerous, and persistent problem that presents a unique challenge to our healthcare system. Unlike uncomplicated UTIs, which are primarily (~95%) monomicrobial with an antibiotic success rate of ~80%, CAUTIs are often polymicrobial (~75%) with a low treatment success rate reaching as low as 40%.
To understand why uncomplicated UTIs and CAUTIs are so different, we did a side-by-side comparison of the two in our recent publication, “CAUTIon - not all UTIs are the same.” We highlight how an uncomplicated UTI is like an unwanted guest knocking on your front door. The bacteria, usually from your own gut flora, find their way to your urethra. Your body's natural defenses, like flushing urine or a thin lining of mucin on the cells of the bladder, act as a barrier. If that barrier is breached, an infection can take hold. But the fight is happening on the doorstep, so to speak. Often, a round of antibiotics can be effective in dealing with the pathogen.
Now, a CAUTI. This is a very different scenario. This is not a guest knocking on the door. This is a party crasher with a master key, let in through a red carpet, given a free pass to the kidneys and bloodstream.
The "master key" here is a simple piece of medical equipment: the urinary catheter. While this flexible tube is an essential, life-saving tool, it is also a foreign object that creates a direct, unfiltered highway for microbes to bypass the body's natural defenses. The problem originates with the catheter itself, which inadvertently injures the delicate lining of the bladder. The body’s natural response is to heal this damage by coating the area and the device with blood proteins, specifically, the clotting factor fibrinogen. However, this healing mechanism is a double-edged sword: while its primary function is to repair the damaged tissue, the fibrinogen layer is also readily exploited by pathogens as a surface for colonization of the catheter and bladder wall. There, they construct a formidable fortress—a sticky, protective layer called a biofilm. Most of these CAUTI pathogens cannot establish an infection without the fibrinogen recruited by catheter-induced bladder inflammation.
The formation of a biofilm is a game-changer in the infection. This slimy, protective matrix effectively shields the microbes from both antibiotics and the body's own immune cells, making the CAUTI incredibly difficult to treat. This fortress allows the pathogens to thrive and potentially spread to other organs, escalating the local infection into a severe, systemic condition like sepsis. In fact, ~25% of the sepsis cases originate from complicated UTIs, specifically CAUTI.
Pathogens involved in these hospital-acquired infections are often more dangerous; they are resistant to multiple drugs like antibiotics and antifungals. While an uncomplicated UTI is most often caused by E. coli, CAUTIs are frequently caused by a wider array of multi-drug resistant pathogens; along with E. coli, this includes various bacterial species, and even fungal pathogens can cause infections. To make matters worse, fungal pathogens provide a unique problem to CAUTIs since they do not induce similar symptoms as bacterial counterparts that let clinicians know you are sick and are not equally as detectable due to hypomorphic phenotypes during infections; thus, oftentimes go undiagnosed and untreated. A bacterial group known as Enterococci poses a significant threat. Previous research demonstrates their ability to act as ecosystem engineers within the catheterized bladder. They actively modify the microenvironment to promote the accumulation of fibrinogen, which in turn creates additional attachment sites for other pathogens. This facilitates the development of a polymicrobial infection, significantly complicating treatment strategies. It is this diverse and resilient community of pathogens that makes CAUTIs such a grave and complex clinical challenge.
The impact of this public health threat is staggering. According to the Centers for Disease Control and Prevention (CDC), CAUTIs are one of the most common hospital-acquired infections. These infections extend hospital stays by an average of 2 to 4 days, increasing susceptibility to bloodstream infections (BSI) due to low antibiotic success. This has put immense pressure on healthcare systems to improve protocols. Thus, the CDC has placed many protocols to minimize infections, following two main pillars:
- Minimizing Catheter Use: We’ve become more vigilant about removing catheters as soon as they are no longer necessary.
- Strict Hygiene: We have very strict protocols for catheter insertion and maintenance to prevent bacteria from entering the system.
This is where real innovation needs to occur. We need to move beyond simple hygiene and protocol and start leveraging our research on CAUTIs to develop novel and innovative solutions that specifically target the unique challenges of these infections.
Imagine a catheter with a surface so slippery that pathogens cannot adhere to it. Or a catheter that releases a targeted, anti-biofilm agent, not a broad-spectrum antibiotic. Imagine using bacteriophages (viruses that specifically infect and kill bacteria) to selectively destroy the pathogens causing the infection, without harming the patient's gut microbiome. Or how about we modify how a patient reacts to catheters and reduce the blood proteins from ever even getting into the bladder. These are not science fiction. These are real, active areas of research that hold the promise of fundamentally changing how we approach this problem.
We have a long way to go, but the path is clear. We must stop treating the CAUTI as just another UTI. We must acknowledge the unique nature of CAUTIs and dedicate our resources to developing targeted, innovative solutions.
Written by: Jonathan Jesus Molina, PhD, and Ana Lidia Flores-Mireles, PhD
- Integrated Biomedical Sciences, University of Notre Dame, Notre Dame, IN, USA.
- Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.